EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association Between Area‐Level Socioeconomic Disadvantage and Immunotherapy in Patients With Non‐Small Cell Lung Cancer

Hiroe Suzuki-Chiba iD, Atsushi Miyawaki, Taiki Hakozaki, Shotaro Aso, Hiroki Matsui, Hideo Yasunaga

Cancer Medicine · 2025

DOI: 10.1002/cam4.71038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hiroe Suzuki-Chiba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Communication, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Healthcare Disparities. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent advances in immunotherapy have improved the survival of patients with non‐small cell lung cancer (NSCLC). However, data on the association between patient socioeconomic status (SES) and the use of immunotherapy remain scarce. We examined the association between area‐level SES and immunotherapy use in patients with stage IV NSCLC in Japan.

Methods

Data from a national inpatient database were used for this analysis. Patients aged ≥ 18 years, hospitalized for stage IV NSCLC, and treated with immunotherapy alone, immunotherapy combined with platinum‐based chemotherapy, and platinum‐based chemotherapy alone as first‐line pharmacotherapy from April 2016 to March 2022 were analyzed. Area‐level SES was measured using the area deprivation index and categorized into quartiles. The primary outcome was the use of immunotherapy as a first‐line treatment. A multivariate linear regression model was used, adjusted for patient characteristics, years, and hospital fixed effects.

Results

A total of 47,291 eligible patients from 843 hospitals, with 22,205 (47%) receiving immunotherapy. Adjusted analyses showed that patients in the most disadvantaged area were less likely to receive immunotherapy compared with those in the least disadvantaged area (adjusted difference, −2.0 percentage points [pp]; 95% confidence interval, −3.6 to −0.5 pp; p = 0.01). Although not significant, this trend persisted when stratified by urban and cancer‐designated hospitals. However, this difference was no longer significant after adjusting for hospital fixed effects.

Conclusion

In Japan, with universal public health insurance with low out‐of‐pocket costs, living in a socioeconomically disadvantaged area is associated with lower rates of immunotherapy use among patients with stage IV NSCLC. These disparities disappeared within the same hospitals using hospital fixed effects; however, such disparities tended to persist in urban, non‐academic, and cancer‐designated hospitals. These findings suggest the need for interventions to address the structural barriers, including those within the hospitals, to optimize NSCLC treatment and reduce health disparities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyHealthcare DisparitiesHumansFemaleMaleAgedMiddle AgedJapanSocial ClassSocioeconomic FactorsAged, 80 and overNeoplasm StagingSocioeconomic Disparities in Health

Stichwörter der Autor:innen

health disparitiesimmunotherapynon‐small cell lung cancersocioeconomic status

Autor:innen und Institutionen

  • Department of Health Communication, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Clinical Epidemiology and Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

ORCID-Profile: Hiroe Suzuki-Chiba

Förderung

  • Ministry of Health, Labour and Welfare

Zitieren

APA

Suzuki-Chiba, H., Miyawaki, A., Hakozaki, T., Aso, S., Matsui, H., & Yasunaga, H. (2025). Association Between Area‐Level Socioeconomic Disadvantage and Immunotherapy in Patients With Non‐Small Cell Lung Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71038

Vancouver

Suzuki-Chiba H, Miyawaki A, Hakozaki T, Aso S, Matsui H, Yasunaga H. Association Between Area‐Level Socioeconomic Disadvantage and Immunotherapy in Patients With Non‐Small Cell Lung Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71038

BibTeX
@article{SuzukiChiba2025,
  author = {Suzuki-Chiba, Hiroe and Miyawaki, Atsushi and Hakozaki, Taiki and Aso, Shotaro and Matsui, Hiroki and Yasunaga, Hideo},
  title = {Association Between Area‐Level Socioeconomic Disadvantage and Immunotherapy in Patients With Non‐Small Cell Lung Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71038}
}
Kostenlos starten →